No superiority for saxagliptin in CVD outcomes study
Results from the phase 4 SAVOR-TIMI-53 trial (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) showed no superiority of saxagliptin (Bristol-Myers Squibb/AstraZeneca) over placebo for a composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke, when added to a patient’s current standard of care (with or without other anti-diabetic therapies) in patients with type 2 diabetes with either a history of established CVD or multiple CVD risk factors. The primary safety objective of non-inferiority was met by saxagliptin.
SAVOR-TIMI-53 is part of an ESC hot-line session dedicated to risk factors and diabetes.
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved in the US, Canada, Europe, and elsewhere as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. From nonrandomized analyses it was hypothesized that this class of drugs might have a protective effect on the vasculature of diabetes patients.
Source: Press release AstraZeneca